GRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

GRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000

The transaction was valued at approximately $672,000. The shares traded represented 3% of the direct equity stake held by the CFO prior to the filing.

The Motley Fool • Sep 9, 2026

Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test

FDA approval is crucial for Galleri's adoption by insurers. The company received some good news from the FDA, and a pivotal meeting is coming up for Grail's Galleri test.

The Motley Fool • Sep 4, 2026

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.

PRNewsWire • Sep 3, 2026

GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference

MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m.

PRNewsWire • Aug 31, 2026

GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting

GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.

MarketBeat • Aug 14, 2026

GRAIL: Looking Beyond The NHS-Galleri Headline

GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.

Seeking Alpha • Aug 12, 2026

FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test

GRAIL Inc. (NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel gears up to evaluate the healthcare company's flagship cancer diagnostic tool.

Benzinga • Aug 10, 2026

US FDA to hold advisory meeting to review Grail's multi-cancer test

Grail said on Friday the U.S. FDA ​plans to hold a ‌meeting of outside experts to review its multi-cancer screening test Galleri ​in September, sending its ​shares up 4% in morning ⁠trade.

Reuters • Aug 7, 2026

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept.

PRNewsWire • Aug 7, 2026